Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Company PLC

http://www.perrigo.com/

Latest From Perrigo Company PLC

US Consumer Health Q2 Earnings Preview: If Not For Headwinds, Tailwinds Would Be Trending

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Consumer Business Strategies

Congressional Appropriators Encourage FDA Guidance On Contraceptive OTC Switches

House and Senate reports again reference sunscreen but add admonishment that FDA “harmonize its approach with international testing standards.” Item exclusive to House report encourages guidance for drug firms on successfully submitting an application for Rx-to-OTC switch of an oral contraceptive.

FDA Prescription To OTC Switch

Stabilizing Formula Business ‘First And Foremost’ For Perrigo To Reach Sustainable Growth

Perrigo’s adjusted operating income from formula business in 2023 was around half the $140m it expects. Level won’t be reached in 2024 but it’s “well on track to recapturing” that amount in 2025 and to “capturing all of that plus in 2026,” says CEO Patrick Lockwood-Taylor.

Business Strategies OTC Drugs

Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results

Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.

Sales & Earnings Women's Health
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Agis Industries
    • Chemagis
    • Clay-Park Labs
    • Cobrek Pharmaceuticals
    • Elan Corporation
    • JB Laboratories
    • Onclave Therapeutics Limited
    • Omega Pharma Invest N.V.
    • Paddock Laboratories
    • Omega Pharma Invest N.V.
    • Ranir Global Holdings LLC
    • Rosemont Pharmaceuticals Ltd.
    • Unico Holdings Inc.
    • Velcera, Inc.
    • Geiss, Destin & Dunn, Inc.
    • High Ridge Brands
UsernamePublicRestriction

Register